Bellevue Group’s Boston Scientific BSX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $92M | Sell |
1,466,894
-92,712
| -6% | -$7.42M | 2.19% | 15 |
|
|
2025
Q4 | $149M | Sell |
1,559,606
-100,243
| -6% | -$9.83M | 2.82% | 12 |
|
|
2025
Q3 | $162M | Sell |
1,659,849
-105,345
| -6% | -$10.9M | 3.37% | 9 |
|
|
2025
Q2 | $190M | Sell |
1,765,194
-185,826
| -10% | -$18.8M | 4.18% | 9 |
|
|
2025
Q1 | $197M | Sell |
1,951,020
-184,275
| -9% | -$18.6M | 4.41% | 9 |
|
|
2024
Q4 | $191M | Sell |
2,135,295
-317,502
| -13% | -$27.9M | 3.67% | 9 |
|
|
2024
Q3 | $206M | Sell |
2,452,797
-116,791
| -5% | -$9.21M | 3.33% | 8 |
|
|
2024
Q2 | $198M | Sell |
2,569,588
-579,088
| -18% | -$42.4M | 3.22% | 7 |
|
|
2024
Q1 | $216M | Sell |
3,148,676
-21,927
| -0.7% | -$1.41M | 3.29% | 6 |
|
|
2023
Q4 | $183M | Buy |
3,170,603
+524,308
| +20% | +$28M | 2.8% | 8 |
|
|
2023
Q3 | $140M | Sell |
2,646,295
-15,157
| -0.6% | -$795K | 2.25% | 11 |
|
|
2023
Q2 | $144M | Sell |
2,661,452
-778,127
| -23% | -$40.6M | 2.05% | 13 |
|
|
2023
Q1 | $172M | Sell |
3,439,579
-463,345
| -12% | -$21.8M | 2.5% | 10 |
|
|
2022
Q4 | $181M | Buy |
3,902,924
+98,877
| +3% | +$4.28M | 2.4% | 10 |
|
|
2022
Q3 | $147M | Sell |
3,804,047
-46,124
| -1% | -$1.85M | 2.11% | 13 |
|
|
2022
Q2 | $143M | Sell |
3,850,171
-63,776
| -2% | -$2.6M | 2.03% | 12 |
|
|
2022
Q1 | $173M | Buy |
3,913,947
+949,916
| +32% | +$41.2M | 2.01% | 12 |
|
|
2021
Q4 | $126M | Sell |
2,964,031
-3,096
| -0.1% | -$130K | 1.3% | 24 |
|
|
2021
Q3 | $129M | Buy |
2,967,127
+640,340
| +28% | +$28.3M | 1.31% | 22 |
|
|
2021
Q2 | $99.5M | Hold |
2,326,787
| – | – | 0.97% | 29 |
|
|
2021
Q1 | $89.9M | Buy |
2,326,787
+116,928
| +5% | +$4.43M | 0.95% | 34 |
|
|
2020
Q4 | $79.4M | Buy |
2,209,859
+323,562
| +17% | +$11.7M | 0.91% | 33 |
|
|
2020
Q3 | $72.1M | Buy |
1,886,297
+155,677
| +9% | +$6M | 1% | 29 |
|
|
2020
Q2 | $60.8M | Buy |
1,730,620
+189,395
| +12% | +$6.82M | 0.86% | 31 |
|
|
2020
Q1 | $50.3M | Sell |
1,541,225
-37,396
| -2% | -$1.46M | 0.98% | 28 |
|
|
2019
Q4 | $71.4M | Buy |
1,578,621
+158,633
| +11% | +$6.64M | 1.13% | 28 |
|
|
2019
Q3 | $57.8M | Buy |
1,419,988
+39,206
| +3% | +$1.66M | 1.07% | 28 |
|
|
2019
Q2 | $59.3M | Buy |
1,380,782
+233,295
| +20% | +$8.97M | 1.01% | 30 |
|
|
2019
Q1 | $44M | Buy |
1,147,487
+90,598
| +9% | +$3.46M | 2.42% | 9 |
|
|
2018
Q4 | $37.4M | Buy |
1,056,889
+77,960
| +8% | +$2.83M | 2.46% | 10 |
|
|
2018
Q3 | $37.7M | Buy |
978,929
+158,333
| +19% | +$5.53M | 2.39% | 10 |
|
|
2018
Q2 | $26.8M | Buy |
820,596
+124,596
| +18% | +$3.76M | 2.29% | 11 |
|
|
2018
Q1 | $19M | Hold |
696,000
| – | – | 1.88% | 16 |
|
|
2017
Q4 | $17.3M | Hold |
696,000
| – | – | 1.8% | 17 |
|
|
2017
Q3 | $20.3M | Buy |
696,000
+68,000
| +11% | +$1.88M | 2.12% | 12 |
|
|
2017
Q2 | $17.4M | Buy |
628,000
+56,000
| +10% | +$1.49M | 2.06% | 12 |
|
|
2017
Q1 | $14.2M | Buy |
572,000
+22,000
| +4% | +$535K | 1.9% | 17 |
|
|
2016
Q4 | $11.9M | Sell |
550,000
-25,000
| -4% | -$545K | 2.44% | 11 |
|
|
2016
Q3 | $13.7M | Buy |
575,000
+75,000
| +15% | +$1.79M | 2.47% | 10 |
|
|
2016
Q2 | $11.7M | Hold |
500,000
| – | – | 2.2% | 11 |
|
|
2016
Q1 | $9.4M | Buy |
+500,000
| New | +$8.78M | 1.71% | 15 |
|
Other funds holding BSX
VCM
VPM
Bellevue Group's BSX Position: Q1 2026 in Review
Bellevue Group reduced its Boston Scientific (BSX) stake by 5.9% in Q1 2026, selling an estimated $7.42M and leaving 1,466,894 shares worth $92M. The position accounts for 2.19% of the portfolio, ranked #15.
Bellevue Group first reported a position in BSX in Q1 2016 and has held it in 41 quarters since. The position peaked at $216M in Q1 2024. 1,664 funds tracked by Wall St. Rank hold BSX as of Q1 2026.
- Bellevue Group held 1,466,894 shares of Boston Scientific worth $92M as of Q1 2026.
- Bellevue Group sold 92,712 Boston Scientific shares in Q1 2026, an estimated $7.42M.
- Boston Scientific made up 2.19% of Bellevue Group's portfolio in Q1 2026, its #15 holding.
- Bellevue Group first reported a position in Boston Scientific in Q1 2016 and has held it in 41 quarters since.
- Bellevue Group's Boston Scientific position peaked at $216M in Q1 2024.
- 1,664 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.
Based on Bellevue Group's 13F filing for Q1 2026, filed 15 May 2026.